Rethinking triple-negative breast cancer treatment through EGFR co-targeting and nanotechnology

Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases

Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC